Literature DB >> 19609980

Synergistic OX40 and CD30 signals sustain CD8+ T cells during antigenic challenge.

Vasileios Bekiaris1, Fabrina Gaspal, Mi-Yeon Kim, David R Withers, Clive Sweet, Graham Anderson, Peter J L Lane.   

Abstract

Prior to acquiring a memory phenotype, antigen-activated CD8(+) T cells need to expand and then undergo a contraction phase. Utilizing two different antigenic stimuli, we provide evidence that the tumor necrosis factor receptors OX40 and CD30 integrate synergistic signals during the expansion phase to help maintain CD8(+) effectors. Thus, double deficiency in OX40 and CD30 leads to CD8(+) cell loss during expansion after immunization either with OVA or with murine CMV. Following their contraction, OX40- and CD30-deficient CD8(+) T cells persist normally in CMV-infected mice. In contrast, persistence after OVA challenge is dependent on OX40 and CD30. Collectively, our data define the important role of both OX40 and CD30 during CD8(+) T-cell activation, and show that long-term CD8 persistence after contraction is regulated not only by stimulatory receptors but also by the nature of the antigen or how the antigen is presented.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609980     DOI: 10.1002/eji.200939424

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  Science gone translational: the OX40 agonist story.

Authors:  Andrew D Weinberg; Nicholas P Morris; Magdalena Kovacsovics-Bankowski; Walter J Urba; Brendan D Curti
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 2.  Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity.

Authors:  Shahram Salek-Ardakani; Michael Croft
Journal:  J Interferon Cytokine Res       Date:  2010-04       Impact factor: 2.607

3.  Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30+ Lymphoma.

Authors:  Jean-Jacques Tudesq; Laure Vincent; Julie Lebrun; Yosr Hicheri; Ludovic Gabellier; Timothé Busetto; Corinne Merle; Nathalie Fegueux; Patrice Ceballos; Philippe Quittet; Robert Navarro; Dominique Hillaire-Buys; Guillaume Cartron
Journal:  Open Forum Infect Dis       Date:  2017-04-05       Impact factor: 3.835

Review 4.  Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Authors:  Georg Maschmeyer; Julien De Greef; Sibylle C Mellinghoff; Annamaria Nosari; Anne Thiebaut-Bertrand; Anne Bergeron; Tomas Franquet; Nicole M A Blijlevens; Johan A Maertens
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

Review 5.  Reprogramming the tumor microenvironment by genome editing for precision cancer therapy.

Authors:  Ke Liu; Jia-Jia Cui; Yan Zhan; Qian-Ying Ouyang; Qi-Si Lu; Dong-Hua Yang; Xiang-Ping Li; Ji-Ye Yin
Journal:  Mol Cancer       Date:  2022-04-11       Impact factor: 27.401

6.  Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity.

Authors:  Fengyang Lei; Jianyong Song; Rizwanul Haque; Mohammad Haque; Xiaofang Xiong; Deyu Fang; Michael Croft; Jianxun Song
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

7.  CD30 Is Dispensable for T-Cell Responses to Influenza Virus and Lymphocytic Choriomeningitis Virus Clone 13 but Contributes to Age-Associated T-Cell Expansion in Mice.

Authors:  Angela C Zhou; Laura M Snell; Michael E Wortzman; Tania H Watts
Journal:  Front Immunol       Date:  2017-09-25       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.